Multidrug resistance proteins in renal cell carcinoma

Folia Biologica

Volumn 54, Issue 6, 2008, Pages 187-192

  Hodorová, Ingrid ^a   Rybarova S ^a   Solar P ^a   Vecanova J ^a   Mihalik, J ^a   Bohus P ^a   Mellova Y ^b   Kluchova D ^a  

^a P J AFÁRIK UNIVERSITY   (Slovakia)

^b University Teaching Hospital in Martin   (Slovakia)

Author keywords

[No Author keywords available]

Indexed keywords

ABC TRANSPORTER; GLYCOPROTEIN P; LUNG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE PROTEIN 1;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PATIENT; CANCER RESISTANCE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; MALE; MULTIDRUG RESISTANCE; NUCLEAR GRADE; ONCOLOGICAL PARAMETERS; PROTEIN EXPRESSION;

EID: 60549093593     PISSN: 00155500     EISSN: 25337602     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Arts, H. J. G., Katsaros, D., de Vries, E. G., Massobrio, M., Genta, F., Danese, S., Arisio, R., Scheper, R. J., Kool, M., Scheffer, G. L., Wilemse, P. H., van der Zee, A. G., Suurmeijer, A. J. H. (1999) Drug resistance-associated markers P-glycoprotein, multidrug resistance-associated protein 1, multidrug resistance-associated protein 2, and lung resistance protein as prognostic factors in ovarian cancer. Clin. Cancer Res. 5, 2798-2805.
2. Avedano, C., Menendez, J. C. (2002) Inhibitors of multidrug resistance to antitumour agents (MDR). Curr. Med. Chem. 9, 159-193.
3. Bush, J. A., Li, G. (2002) Cancer chemoresistance: relationship between p53 and multidrug transporters. Int. J. Cancer 98, 323-330.
4. Buzaid, A. C., Todd, M. B. (1989) Therapeutic options in renal cell carcinoma. Semin. Oncol. 16 (suppl 6), 12-16.
5. Campbell, S. C. (2006) Prognostic factors for renal cell carcinoma: integrating laboratory and molecular factors. J. Urol. 175 (3PtI), 813-814.
6. Cole, S. P., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Setwart, A. J., Kurz, E. U., Duncan, A. M., Deeley, R. G. (1992) Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 258, 1650-1654.
7. Duensing, S., Dallmann, I., Gross, J. (1994) Immunohistochemical detection of P-glycoprotein: initial expression correlates with survival in renal cell carcinoma patients. Oncology 51, 309-313.
8. Filipits, M., Drach, J., Pohl, G., Schuster, J., Stranzl, T., Ackermann, J., Königsberg, R., Kaufmann, H., Gisslinger, H., Huber, H., Ludwig, H., Pirker R. (1999) Expression of the lung resistance protein predicts poor outcome in patients with multiple myeloma. Clin. Cancer Res. 5, 2426-2430.
9. Fojó, A. T., Ueda, K., Slamon, D. J., Poplack, D. G., Gottesman, M. M., Pastan, I. (1987) Expression of a multidrug-resistance gene in human tumours and tissues. Proc. Natl. Acad. Sci. USA 84, 265-269.
10. Fukuda, M., Satomi, Y., Asakura, T. (1998) Prognosis in the cases with renal cell carcinoma according to clinical parameters. Nippon Hinyokika Gakkai Zasshi 89, 647-656. (in Japanese)
11. Hait, W. N., Yang, J. M. (2006) The individualization of cancer therapy. The unexpected role of p53. Trans. Am. Clin. Climatol. Assoc. 117, 85-101.
12. Hinoshita, E., Uchiumi, T., Taguchi, K., Kinukawa, N., Tsuneyoshi, M., Maehara Y., Sugimachi, K., Kuwano, M. (2000) Increased expression of an ATP-binding cassette superfamily transporter, Multidrug resistance protein 2, in human colorectal carcinomas. Clin. Cancer Res. 6, 2401-2407.
13. Izquierdo, M. A., Jedlitschky, G., Leier, I., Buchholz, U., Hummel-Eisenbeiss, J., Burchell B., Scheffer, G. L., Flens, M. J., Giaccone, G., Broxterman, H.J., Meijer, C. J., van der Valk, P., Scheper, R. J. (1996) Broad distribution of the multidrug resistance-related vault lung resistance protein in normal human tissues and tumours. Am. J. Pathol. 3, 877-887.
14. Keppler, D., König, J. (1997) Expression and localization of the conjugate export pump encoded by the MRP2 (cMRP/cMOAT) gene in liver. FASEB J. 11, 509-516.
15. Kong, C. Z., Zeng, Y,, Wu, X. X., Li, J. Q., Zhu, Y. Y., Chen, Y. (2004) Increased expression of lung resistance-related protein in lower grade urothelial carcinoma of the renal pelvis and ureter. Int. J. Urol. 11, 721-727.
16. Koshiyama, M., Yoshida, M., Fuji, H., Konishi, M., Nanno, H., Hayashi, M., Tauchi, K. (1999) Expression of multidrug resistance-associated protein in endometrial carcinomas: correlation with clinicopathology and prognosis. Ann. Diagn. Pathol. 3, 81-87.
17. Legrand, O., Simonin, G., Perrot, J. Y., Zittoun, R., Marie, J. P. (1998) Pgp and MRP activities using calcein-AM are prognostic factors in adult acute myeloid leukemia patients. Blood 91, 4480-4488.
18. Loe, D. W., Deeley, R. G., Cole, S. P. (1998) Characterization of vincristine transport by the M(r) 190,000 multidrug resistance protein (MRP): evidence for cotransport with reduced glutathione. Cancer Res. 58, 5130-5136.
19. Meijer, G. A., Schroeijers, A. B., Flens, M. J., Meuwissen, S. G., van der Valk, P., Bank, J. P., Scheper, R. J. (1999) Increased expression of multidrug resistance related proteins Pgp, MRP1, and LRP/MVP occurs early in colorectal carcinogenesis. J. Clin. Pathol. 52, 450-454.
20. Mignogna, C. H., Staibano, S., Altieri V., de Rosa, G., Pannone, G., Santoro, A., Zamperese, R., D'Arminento, M., Rocchetti, R., Mezza, E., Nasti, M., Strazzullo, V., Montanaro, V., Mascolo, M., Bufo, P. (2006) Prognostic significance of multidrug-resistance protein (MDR1) in renal clear cell carcinomas: A five year follow-up analysis. BMC Cancer 6, 293.
21. Nooter, K., Brutel de la Riviera, G., Look, M. P., van Wingerden, K. E., Henzen-Logmans, S. C., Scheper, R. J., Flens, M. J., Klijn, J. G., Stoter, G., Foekens, J. A. (1997) The prognostic significance of expression of the multidrug resistance-associated protein (MRP) in primary breast cancer. Br. J. Cancer 76, 486-493.
22. Oshika, Y., Nakamura, M., Tokunaga, T., Fukushima, Y, Abe, Y., Ozeki, Y., Yamazaki, H., Tamaoki, N., Ueyama, Y. (1998) Multidrug resistance-associated protein and mutant p53 protein expression in non-small cell lung cancer. Mod. Pathol. 11, 1059-1063.
23. Pantuck, A. J., Zisman, A., Belldegrun, A. S. (2001) The changing natural history of renal cell carcinoma. J. Urol. 166, 1611-1623.
24. Patard, J. J., Rodriguez, A., Rioux-Leclercq, N., Guillé, F., Lonel, B. (2002) Prognostic significance of the mode of detection in renal tumours. BJU Int. 90, 358-363.
25. Paulusma, C. C., Bosma, P. J., Zaman, G. J. R., Bakker, C. T., Otter, M., Scheffer, G. L., Scheper, R. J., Borste, P., Oude Elferink, R. P. (1996) Congenital jaundice in rats with a mutation in multidrug resistance-associated protein gene. Science 271, 1126-1128.
26. Rybárová, S., Hajduková, M., Hodorová, I., Kočišová, M., Böör, A., Brabemcová, E., Kasan, P., Biroš, E., Mojžiš, J., Mirossay, L. (2004) Expression of the multidrug resistance-associated protein 1 (MRP1) and the lung resistance-related protein (LRP) in human lung cancer. Neoplasma 51, 169-174.
27. Sakeda, T., Nakamura, T., Okumura, K. (2002) MDR1 Genotype-related pharmacokinetics and pharmacodynamics. Biol. Pharm. Bull. 25, 1391-1400.
28. Sampath, J., Sun, D., Kidd, V. J. (2001) Mutant p53 cooperates with ETS and selectively up-regulates human MDR1 not MRP1. Biol. Chem. 276, 39359-39367.
29. Sarkadi, B., Ozvegy-Laczka, C., Nemet, K., Varádi, A. (2004) ABCG2 - a transporter for all seasons. FEBS Lett. 567, 116-120.
30. Schaub, T. P., Kartenbeck, J., König J, Spring, H., Dörsam, J., Staehler, G., Störkel, S., Thon, W. F., Keppler, D. (1999) Expression of the MRP2 gene-encoded conjugate export pump in human kidney proximal tubules and in renal cell carcinoma. J. Am. Soc. Nephrol. 10, 1159-1169.
31. Tsui, K. H., Shvarts, O., Smith, R. B., Figlin, R. A., Dekernion, J. B., Belldegrun, A. (2000) Renal cell carcinoma: prognostic significance of incidentally detected tumours. J. Urol. 163, 426-430.
32. Wang, Q., Beck, T. (1998) Transcriptional supression of multidrug resistance-associated protein (MRP) gene expression by wild-type p53. Cancer Res. 58, 5762-5769.
33. Zisman, A., Pantuck, A. J., Wieder, J., Chao, D. H., Dorsey, F., Said, J. W., de Kernion, J. B., Figlin, R. A., Belldegrun, A. (2002) Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J. Clin. Oncol. 20, 4559-4566.